19 02, 2021

GIST Expert Dr. Jason Sicklick & Team Release New Study on What Drives GIST

By |2021-02-19T08:58:23-05:00February 19th, 2021|GIST Education, News|

In a recent study, researchers at University of California San Diego School of Medicine identified new therapeutic targets that could lead to new treatment options for patients. The study, published in the February 18, 2021 online edition of Oncogene, found that specific cell-to-cell communication influences GIST biology and is strongly associated with cancer progression and metastasis.

3 12, 2020

Custo efetividade do teste genético para pacientes recém diagnosticados com GIST

By |2020-12-03T14:49:35-05:00December 3rd, 2020|Global, News|

Em um artigo publicado em 29 de setembro de 2020, na revista "JAMA Network Open", o Dr. Jason Sicklick, Moores Cancer Center, UCSD, e colegas relataram que o teste genético é custo-efetivo e benéfico para pacientes com GIST metastático recém-diagnosticados. .

15 10, 2020

Pruebas genéticas costo efectivas para GIST recién diagnosticados

By |2020-10-15T09:09:24-04:00October 15th, 2020|Global, News, Research|

En un artículo publicado el 29 de septiembre de 2020 en la revista “JAMA Network Open”, Dr. Jason Sicklick, Moores Cancer Center, UCSD y sus colegas informaron que las pruebas genéticas son costo efectivas y beneficiosas para los pacientes recién diagnosticados con GIST metastásico.

28 09, 2020

Genetic Testing Cost Effective for Newly Diagnosed GIST

By |2020-09-28T14:32:47-04:00September 28th, 2020|News, Research|

UC San Diego Health released a post today titled, "Genetic Testing Cost Effective for Newly Diagnosed GIST" discussing a new paper published in JAMA Network Open by Moores Cancer Center's Dr. Jason Sicklick and colleagues which covered genetic testing for GIST patients.

14 07, 2020

RARE Partnership in Advocacy, Funding, and Research for Gastrointestinal Stromal Tumor

By |2021-01-13T11:53:21-05:00July 14th, 2020|Advocacy, News, Research, SDH-Deficient GIST|

Partnerships and collaborations are critical to the progress of research in rare diseases. GIST specialist & Pediatric & SDH-Deficient GIST Consortium member, Dr. Jason Sicklick, and LRG member, Debra Melikian, are working together find a cure for succinate dehydrogenase-deficient gastrointestinal stromal tumors (SDH-deficient GIST), a hereditary rare cancer syndrome which claimed the lives of Debra’s husband and her son Merak.

4 02, 2020

Patient Advocate’s Story Unfolds in RARE Revolution Magazine

By |2020-02-04T08:53:11-05:00February 4th, 2020|Advocacy, News, SDH-Deficient GIST|

Deb Melikian, patient advocate, and Dr. Jason Sicklick, GIST expert & researcher, share the story of their unique partnership which began at an LRG GIST Day of Learning in the rare partners issue of RARE Revolution Magazine.

16 09, 2019

LRG Webcast Series: Updates on the Temozolomide Trial

By |2020-07-09T17:44:13-04:00September 16th, 2019|Clinical Trials, SDH-Deficient GIST, Webcast|

Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.

30 08, 2019

New Horizons – Pediatric & SDH-Deficient GIST Consortium Update: A Review with Experts & Advocates

By |2019-08-30T10:37:28-04:00August 30th, 2019|Events, Global, Video|

A Pediatric & SDH-Deficient GIST Consortium Update: A Review with Experts & Advocates presented by Jayne Bressington, Becky Owens, and Dr. Jason Sicklick at New Horizons 2019 in Wayne, NJ.

Need a new search?

If you didn't find what you were looking for, try a new search!

Go to Top